Research ExplorerPublicationsAdjunctive use of reboxetine in schizophrenia.

Adjunctive use of reboxetine in schizophrenia.

Standard

Adjunctive use of reboxetine in schizophrenia. / Raedler, Thomas J; Jahn, Holger; Arlt, Josef; Kiefer, Falk; Schick, Mildred; Naber, Dieter; Wiedemann, Klaus.

In: EUR PSYCHIAT, Vol. 19, No. 6, 6, 2004, p. 366-369.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Raedler, TJ, Jahn, H, Arlt, J, Kiefer, F, Schick, M, Naber, D & Wiedemann, K 2004, 'Adjunctive use of reboxetine in schizophrenia.', EUR PSYCHIAT, vol. 19, no. 6, 6, pp. 366-369. <http://www.ncbi.nlm.nih.gov/pubmed/15363476?dopt=Citation>

APA

Raedler, T. J., Jahn, H., Arlt, J., Kiefer, F., Schick, M., Naber, D., & Wiedemann, K. (2004). Adjunctive use of reboxetine in schizophrenia. EUR PSYCHIAT, 19(6), 366-369. [6]. http://www.ncbi.nlm.nih.gov/pubmed/15363476?dopt=Citation

Vancouver

Raedler TJ, Jahn H, Arlt J, Kiefer F, Schick M, Naber D et al. Adjunctive use of reboxetine in schizophrenia. EUR PSYCHIAT. 2004;19(6):366-369. 6.

Bibtex

@article{3737a05d3019415d967011a604edd69d,
title = "Adjunctive use of reboxetine in schizophrenia.",
abstract = "BACKGROUND: Schizophrenia is frequently complicated by depressive or negative symptoms that respond only moderately to treatment with antipsychotic drugs. Reboxetine is a novel antidepressant, which inhibits the reuptake of norepinephrine. We sought to study the efficacy and tolerability of the adjunctive use of reboxetine in a cohort of schizophrenic patients with prominent depressive or negative symptoms. METHODS: Sixteen schizophrenic inpatients were recruited for this study. All subjects received 4-8 mg of reboxetine/day while the antipsychotic medication (typical antipsychotics = 4; atypical antipsychotics = 12) was continued. All subjects underwent a standardized assessment including PANSS, CGI, HAMD, and CDSS before and after treatment with reboxetine (mean 26 +/- 17 d). RESULTS: All subjects tolerated treatment with reboxetine. Adverse effects were mild and did not require discontinuation of reboxetine. All clinical scores (PANSS 93.1 vs. 63.1; CGI 5.4 vs. 4.1; HAMD 20.4 vs. 8.1; CDSS 12.5 vs. 4.6) improved significantly under adjunctive treatment with reboxetine (all P <0.01). CONCLUSION: The adjunctive use of reboxetine in schizophrenic patients was safe and well-tolerated. Our results suggest that the adjunctive use of reboxetine may be an effective treatment for depressive and negative symptoms in schizophrenia.",
author = "Raedler, {Thomas J} and Holger Jahn and Josef Arlt and Falk Kiefer and Mildred Schick and Dieter Naber and Klaus Wiedemann",
year = "2004",
language = "Deutsch",
volume = "19",
pages = "366--369",
journal = "EUR PSYCHIAT",
issn = "0924-9338",
publisher = "Elsevier Masson",
number = "6",

}

RIS

TY - JOUR

T1 - Adjunctive use of reboxetine in schizophrenia.

AU - Raedler, Thomas J

AU - Jahn, Holger

AU - Arlt, Josef

AU - Kiefer, Falk

AU - Schick, Mildred

AU - Naber, Dieter

AU - Wiedemann, Klaus

PY - 2004

Y1 - 2004

N2 - BACKGROUND: Schizophrenia is frequently complicated by depressive or negative symptoms that respond only moderately to treatment with antipsychotic drugs. Reboxetine is a novel antidepressant, which inhibits the reuptake of norepinephrine. We sought to study the efficacy and tolerability of the adjunctive use of reboxetine in a cohort of schizophrenic patients with prominent depressive or negative symptoms. METHODS: Sixteen schizophrenic inpatients were recruited for this study. All subjects received 4-8 mg of reboxetine/day while the antipsychotic medication (typical antipsychotics = 4; atypical antipsychotics = 12) was continued. All subjects underwent a standardized assessment including PANSS, CGI, HAMD, and CDSS before and after treatment with reboxetine (mean 26 +/- 17 d). RESULTS: All subjects tolerated treatment with reboxetine. Adverse effects were mild and did not require discontinuation of reboxetine. All clinical scores (PANSS 93.1 vs. 63.1; CGI 5.4 vs. 4.1; HAMD 20.4 vs. 8.1; CDSS 12.5 vs. 4.6) improved significantly under adjunctive treatment with reboxetine (all P <0.01). CONCLUSION: The adjunctive use of reboxetine in schizophrenic patients was safe and well-tolerated. Our results suggest that the adjunctive use of reboxetine may be an effective treatment for depressive and negative symptoms in schizophrenia.

AB - BACKGROUND: Schizophrenia is frequently complicated by depressive or negative symptoms that respond only moderately to treatment with antipsychotic drugs. Reboxetine is a novel antidepressant, which inhibits the reuptake of norepinephrine. We sought to study the efficacy and tolerability of the adjunctive use of reboxetine in a cohort of schizophrenic patients with prominent depressive or negative symptoms. METHODS: Sixteen schizophrenic inpatients were recruited for this study. All subjects received 4-8 mg of reboxetine/day while the antipsychotic medication (typical antipsychotics = 4; atypical antipsychotics = 12) was continued. All subjects underwent a standardized assessment including PANSS, CGI, HAMD, and CDSS before and after treatment with reboxetine (mean 26 +/- 17 d). RESULTS: All subjects tolerated treatment with reboxetine. Adverse effects were mild and did not require discontinuation of reboxetine. All clinical scores (PANSS 93.1 vs. 63.1; CGI 5.4 vs. 4.1; HAMD 20.4 vs. 8.1; CDSS 12.5 vs. 4.6) improved significantly under adjunctive treatment with reboxetine (all P <0.01). CONCLUSION: The adjunctive use of reboxetine in schizophrenic patients was safe and well-tolerated. Our results suggest that the adjunctive use of reboxetine may be an effective treatment for depressive and negative symptoms in schizophrenia.

M3 - SCORING: Zeitschriftenaufsatz

VL - 19

SP - 366

EP - 369

JO - EUR PSYCHIAT

JF - EUR PSYCHIAT

SN - 0924-9338

IS - 6

M1 - 6

ER -